Akebia Therapeutics
AKBA
103 hedge funds and large institutions have $57.4M invested in Akebia Therapeutics in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 32 closing their positions.
117% more call options, than puts
Call options by funds: $1.11M | Put options by funds: $510K
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.39% less ownership
Funds ownership: 27.24% → 26.85% (-0.39%)
10% less funds holding
Funds holding: 114 → 103 (-11)
28% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 32
45% less capital invested
Capital invested by funds: $104M → $57.4M (-$46.9M)
Top Buyers
| 1 |
BlackRock
New York
|
+$11.2M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.36M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.59M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.3M |
| 5 |
Bank of New York Mellon
New York
|
+$724K |
Top Sellers
| 1 |
AIM
Alerce Investment Management
Chicago,
Illinois
|
-$9.22M |
| 2 |
Millennium Management
New York
|
-$3.98M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.87M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.54M |
| 5 |
Goldman Sachs
New York
|
-$1.32M |
AKBA Hedge Fund Activity: Q2 2024 in Review
103 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2024, worth a combined $57.4M — down 45% from $104M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of AKBA and 23 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 31 added.
The largest buyer was BlackRock, adding an estimated $11.2M. The largest seller was Alerce Investment Management, cutting an estimated $9.22M.
- 103 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2024, down from 114 in Q1 2024.
- Funds reported $57.4M of Akebia Therapeutics stock for Q2 2024, down 45% quarter-over-quarter.
- 23 funds opened new Akebia Therapeutics positions in Q2 2024 and 32 closed out, a net change of -9 holders.
- The largest Akebia Therapeutics buyer in Q2 2024 was BlackRock, an estimated $11.2M added.
- The largest Akebia Therapeutics seller in Q2 2024 was Alerce Investment Management, an estimated $9.22M sold.
Based on aggregated 13F filings for Q2 2024.